Clariant
Market Cap
CHF5.8b
Last Updated
2020/08/05 21:46 UTC
Data Sources
Company Financials +
Executive Summary
Clariant AG, together with its subsidiaries, develops, manufactures, distributes, and sells specialty chemicals worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Adequate balance sheet with moderate growth potential.
Similar Companies
Share Price & News
How has Clariant's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CLN has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-1.1%
CLN
-0.9%
CH Chemicals
-1.1%
CH Market
1 Year Return
0.4%
CLN
39.6%
CH Chemicals
5.0%
CH Market
Return vs Industry: CLN underperformed the Swiss Chemicals industry which returned 42.5% over the past year.
Return vs Market: CLN underperformed the Swiss Market which returned 5.4% over the past year.
Shareholder returns
| CLN | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.1% | -0.9% | -1.1% |
| 30 Day | 0.3% | 6.8% | -0.7% |
| 90 Day | 1.0% | 19.2% | 5.0% |
| 1 Year | 17.9%0.4% | 44.2%39.6% | 8.6%5.0% |
| 3 Year | -2.0%-20.4% | 57.3%42.4% | 19.4%7.0% |
| 5 Year | 17.8%-8.9% | 105.7%76.7% | 29.5%9.1% |
Price Volatility Vs. Market
How volatile is Clariant's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Clariant's(VTX:CLN) Share Price Is Down 18% Over The Past Three Years.1 month ago | Simply Wall St
Don't Buy Clariant AG (VTX:CLN) For Its Next Dividend Without Doing These Checks1 month ago | Simply Wall St
Why Clariant AG (VTX:CLN) Could Be Worth WatchingValuation
Is Clariant undervalued compared to its fair value and its price relative to the market?
41.31x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CLN (CHF17.68) is trading above our estimate of fair value (CHF17.12)
Significantly Below Fair Value: CLN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CLN is poor value based on its PE Ratio (41.3x) compared to the CH Chemicals industry average (38.3x).
PE vs Market: CLN is poor value based on its PE Ratio (41.3x) compared to the Swiss market (20.9x).
Price to Earnings Growth Ratio
PEG Ratio: CLN is poor value based on its PEG Ratio (2.6x)
Price to Book Ratio
PB vs Industry: CLN is good value based on its PB Ratio (2.4x) compared to the CH Chemicals industry average (5.2x).
Next Steps
Future Growth
How is Clariant forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
15.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLN's forecast earnings growth (15.8% per year) is above the savings rate (-0.2%).
Earnings vs Market: CLN's earnings (15.8% per year) are forecast to grow faster than the Swiss market (9.3% per year).
High Growth Earnings: CLN's earnings are forecast to grow, but not significantly.
Revenue vs Market: CLN's revenue (4.9% per year) is forecast to grow faster than the Swiss market (3.7% per year).
High Growth Revenue: CLN's revenue (4.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CLN's Return on Equity is forecast to be low in 3 years time (12%).
Next Steps
Past Performance
How has Clariant performed over the past 5 years?
-23.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CLN has a large one-off gain of CHF78.0M impacting its June 30 2020 financial results.
Growing Profit Margin: CLN became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: CLN's earnings have declined by 23.5% per year over the past 5 years.
Accelerating Growth: CLN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CLN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Chemicals industry (9.3%).
Return on Equity
High ROE: CLN's Return on Equity (6.6%) is considered low.
Next Steps
Financial Health
How is Clariant's financial position?
Financial Position Analysis
Short Term Liabilities: CLN's short term assets (CHF3.9B) exceed its short term liabilities (CHF2.3B).
Long Term Liabilities: CLN's short term assets (CHF3.9B) exceed its long term liabilities (CHF2.8B).
Debt to Equity History and Analysis
Debt Level: CLN's debt to equity ratio (81.1%) is considered high.
Reducing Debt: CLN's debt to equity ratio has reduced from 103.6% to 81.1% over the past 5 years.
Debt Coverage: CLN's debt is well covered by operating cash flow (22.8%).
Interest Coverage: CLN's interest payments on its debt are not well covered by EBIT (2.4x coverage).
Balance Sheet
Next Steps
Dividend
What is Clariant current dividend yield, its reliability and sustainability?
3.11%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CLN's dividend (3.11%) is higher than the bottom 25% of dividend payers in the Swiss market (1.8%).
High Dividend: CLN's dividend (3.11%) is low compared to the top 25% of dividend payers in the Swiss market (3.88%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, CLN has been paying a dividend for less than 10 years.
Growing Dividend: CLN's dividend payments have increased, but the company has only paid a dividend for 8 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (128.5%), CLN's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: CLN's dividends in 3 years are forecast to be covered by earnings (53.2% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.1yrs
Average management tenure
CEO
Hariolf Kottmann (65 yo)
1.08yrs
Tenure
CHF788,806
Compensation
Dr. Hariolf Kottmann serves as Executive Chairman of Clariant International Ltd. He has been President of Conseil Européen De L'industrie Chimique - European since October 7, 2016. Dr. Kottmann had been th ...
CEO Compensation Analysis
Compensation vs Market: Hariolf's total compensation ($USD861.71K) is below average for companies of similar size in the Swiss market ($USD2.48M).
Compensation vs Earnings: Hariolf's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Executive Chairman | 1.08yrs | CHF788.81k | 0.13% CHF 7.6m | |
| Head of Business Unit Additives | 0.33yr | no data | no data | |
| Executive VP & COO | 1.08yrs | no data | 0.031% CHF 1.8m | |
| CTO and Head of Group Technology & Innovation | no data | no data | no data | |
| Senior Investor Relations Officer | no data | no data | no data | |
| Head of Legal Department | no data | no data | no data | |
| Head of Corporate Communications | no data | no data | no data | |
| Head of Global Marketing | no data | no data | no data | |
| Head of Group Human Resources | no data | no data | no data | |
| Country Head of Switzerland | no data | no data | no data | |
| Head of Business Unit Oil & Mining Services | 7.75yrs | no data | no data | |
| Executive VP & Chief Transformation Officer | 0.75yr | no data | 0.017% CHF 1.0m |
1.1yrs
Average Tenure
60yo
Average Age
Experienced Management: CLN's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Executive Chairman | 1.08yrs | CHF788.81k | 0.13% CHF 7.6m | |
| Independent Lead Director | 1.08yrs | CHF444.94k | 0.0061% CHF 354.0k | |
| Independent Non-Executive Director | 9.58yrs | CHF309.02k | 0.020% CHF 1.1m | |
| Independent Non-Executive Director | 4.33yrs | CHF360.00k | 0.0043% CHF 248.1k | |
| Independent Non Executive Director | 9.58yrs | CHF290.00k | 1.85% CHF 107.5m | |
| Independent Non-Executive Director | 5.42yrs | CHF299.70k | 0.36% CHF 20.8m | |
| Independent Non-Executive Director | 4.33yrs | CHF299.17k | 0.0046% CHF 267.3k | |
| Independent Vice Chairman of the Board | 0.58yr | CHF295.69k | 0.00066% CHF 38.4k | |
| Independent Non-Executive Director | 1.83yrs | CHF308.77k | 0.00066% CHF 38.4k | |
| Independent Director | 1.83yrs | CHF303.28k | 0.00066% CHF 38.4k | |
| Non-Executive Director | 0.17yr | no data | no data | |
| Non-Executive Director | 0.17yr | no data | no data |
1.8yrs
Average Tenure
61.5yo
Average Age
Experienced Board: CLN's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Clariant AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Clariant AG
- Ticker: CLN
- Exchange: SWX
- Founded: 1886
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: CHF5.823b
- Shares outstanding: 329.35m
- Website: https://www.clariant.com
Number of Employees
Location
- Clariant AG
- Rothausstrasse 61
- Muttenz
- Basel-Landschaft
- 4132
- Switzerland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CLRN | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jun 1995 |
| CLN | SWX (SIX Swiss Exchange) | Yes | Ordinary Shares | CH | CHF | Jun 1995 |
| 0QJS | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | CHF | Jun 1995 |
| CLRN | XTRA (XETRA Trading Platform) | Yes | Ordinary Shares | DE | EUR | Jun 1995 |
| CLZN.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jun 1995 |
| CLZN.Y | OTCPK (Pink Sheets LLC) | ADR EACH REPR 1 COM | US | USD | Oct 2008 | |
| CLRS | DB (Deutsche Boerse AG) | ADR EACH REPR 1 COM | DE | EUR | Oct 2008 |
Biography
Clariant AG, together with its subsidiaries, develops, manufactures, distributes, and sells specialty chemicals worldwide. It operates in four segments: Care Chemicals, Catalysis, Natural Resources, and Pl ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/08/05 21:46 |
| End of Day Share Price | 2020/08/04 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.